JBCHEPHARM - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.7
| Stock Code | JBCHEPHARM | Market Cap | 35,293 Cr. | Current Price | 2,198 ₹ | High / Low | 2,300 ₹ |
| Stock P/E | 51.6 | Book Value | 251 ₹ | Dividend Yield | 1.00 % | ROCE | 24.8 % |
| ROE | 18.4 % | Face Value | 1.00 ₹ | DMA 50 | 2,132 ₹ | DMA 200 | 1,956 ₹ |
| Chg in FII Hold | 1.45 % | Chg in DII Hold | -1.97 % | PAT Qtr | 116 Cr. | PAT Prev Qtr | 179 Cr. |
| RSI | 54.9 | MACD | 24.5 | Volume | 3,45,904 | Avg Vol 1Wk | 2,30,752 |
| Low price | 1,603 ₹ | High price | 2,300 ₹ | PEG Ratio | 2.46 | Debt to equity | 0.00 |
| 52w Index | 85.4 % | Qtr Profit Var | -22.6 % | EPS | 42.0 ₹ | Industry PE | 32.1 |
J.B. Chemicals & Pharmaceuticals (JBCHEPHARM) shows moderate potential for swing trading. The current price of ₹2,198 is above both the 50 DMA (₹2,132) and 200 DMA (₹1,956), reflecting bullish momentum. RSI at 54.9 suggests neutral-to-positive strength, while MACD at 24.5 confirms upward momentum. Fundamentals are decent with ROCE at 24.8% and ROE at 18.4%. EPS of ₹42.0 supports profitability, but the high P/E of 51.6 compared to industry PE of 32.1 indicates overvaluation. Quarterly PAT declined from ₹179 Cr. to ₹116 Cr., showing near-term weakness. Debt-free balance sheet adds stability.
✅ Optimal Entry Price: Around ₹2,120–₹2,140 (near 50 DMA support)
📈 Exit Strategy (if already holding): Consider exiting near ₹2,280–₹2,300 (resistance zone close to recent high).
---
🌟 Positive
- 📈 Strong [ROCE](ca://s?q=Explain_ROCE) of 24.8% and [ROE](ca://s?q=Explain_ROE) of 18.4% indicate efficient capital use.
- 💰 Dividend yield of 1.00% provides income support.
- 📊 EPS of ₹42.0 reflects profitability.
- 📉 Debt-to-equity ratio of 0.00 ensures financial stability.
⚠️ Limitation
- 📉 High P/E of 51.6 compared to industry PE of 32.1 suggests overvaluation.
- 📊 PEG ratio of 2.46 indicates expensive valuation relative to growth.
- 📉 Quarterly PAT declined from ₹179 Cr. to ₹116 Cr., showing near-term weakness.
- 📊 DII holdings decreased (-1.97%), reflecting reduced domestic institutional confidence.
📰 Company Negative News
- 📉 Decline in quarterly profits (-22.6%).
- 📊 Valuation concerns due to high P/E and PEG ratio.
📢 Company Positive News
- 💡 FII holdings increased (+1.45%), showing foreign investor confidence.
- 📈 Strong trading volume (3,45,904 vs. avg 2,30,752) indicates active participation.
- 📊 Stock trading above DMA levels confirms bullish momentum.
🏭 Industry
- 📊 Industry PE is 32.1, while JBCHEPHARM trades at 51.6, making it relatively expensive compared to peers.
- 🌐 Pharmaceutical sector remains resilient with steady demand outlook.
✅ Conclusion
JBCHEPHARM is a moderately attractive swing trade candidate with entry near ₹2,120–₹2,140 and exit around ₹2,280–₹2,300. Fundamentals are strong with zero debt and decent ROE, but valuation risks and declining quarterly profits warrant caution. Momentum indicators favor a bullish bias in the short term, making it suitable for cautious swing trading.
Would you like me to extend this with a peer comparison against Aurobindo Pharma and Cipla, or a broader pharma sector outlook to evaluate relative swing trade opportunities?